FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026

Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Other Events. FAETH THERAPEUTICS PIKTOR Phase 2 Endometrial Cancer Topline Results NOVEMBER 9, 2026 Exhibit 99.1 This Presentation contains forward-looking statements of Faeth Therapeutics, Inc. (the “Company”) within the meaning of the federal securities laws. Words such as “may,” “will,” “sh

Event · Clinical / regulatory
Product
PIKTOR
Milestone
topline data
Indication
advanced endometrial cancer

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 9, 2026, 1:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 1:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$FTH
Bullish
high confidence
Mentioned
$FTH
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FTHBullishMed
01

Why it matters

The results provide the first quantitative efficacy readout, which could shift analyst coverage and trigger short‑term buying.

02

Market read

Early positive oncology data often move small‑cap biotech stocks; investors will watch for follow‑on trial designs.

03

What to watch

Potential safety signals and the need for a pivotal trial could delay commercialization and dilute impact.

Relevance 8/10Novelty 8/10Timing: today

Background

The filing is an SEC Form 8‑K announcing first‑time public disclosure of Phase 2 results for Faeth's PIKTOR combination therapy.

Company-level read

Ticker impact

$FTHBullishHigh confidence
Context

Faeth Therapeutics disclosed Phase 2 PIKTOR trial results showing 33% ORR and 7.4‑month median PFS in advanced endometrial cancer.

Expected impact

likely upward pressure as the market prices in the encouraging efficacy signals.

Evidence & confidence

Phase 2 data are a material catalyst for a biotech; the disclosed response rates exceed typical benchmarks and suggest a viable path to registration.

Market effects

Strengthens the PI3K/AKT/mTOR inhibitor niche and may boost peer biotech valuations.

U.S. biotech sector could see modest gains on the back of the data.

Limited to investors focused on oncology pipelines; no broad market effect.

Counterpoint

Data are early‑stage and single‑arm; efficacy may not translate to later trials, risking overvaluation.

Key entities

  • Faeth Therapeutics, Inc.

    Biotech developing the PIKTOR oral PI3K/AKT/mTOR inhibitor.

  • Anand Parikh

    CEO and co‑founder presenting the data.

Related articles

$FTHMed

Why is Faeth Therapeutics stock surging today?

Faeth Therapeutics (FTH) stock rose 10.1% in pre-market trading after presenting Phase II endometrial cancer data at the Jefferies Global Healthcare Conference, showing a 33% overall response rate. The company also announced a clinical partnership with Roche. H.C. Wainwright reiterated its Buy rating and $60 price target, citing a 55% stock decline since November 9 as disconnected from clinical progress.

$FTHMed

Faeth Therapeutics stock gets $60 target on Roche collaboration

Faeth Therapeutics (FTH) received a $60 price target from H.C. Wainwright after announcing a clinical trial collaboration with Roche to evaluate PIKTOR in combination with giredestrant for advanced breast cancer. The stock has fallen 55% since November 9, trading at $9.28. Analysts cite undervaluation and positive Phase 2 trial results for PIKTOR in endometrial cancer, with a 33% response rate.

$FTHMedAI 8/10

Baird reiterates Faeth Therapeutics stock rating on PIK-201 data

Baird reiterated an Outperform rating on Faeth Therapeutics (FTH) with a $57 price target, citing positive PIK-201 data. The stock is down 35% in a week, trading at $12.79. Analysts highlight its potential in endometrial and breast cancer, with a market cap of $333M and strong financial metrics. Recent clinical trials showed a 33% response rate in endometrial cancer.

$FTHHighAI 8/10

Faeth Therapeutics stock rating reiterated at Buy by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating and $60 price target for Faeth Therapeutics (FTH) after positive Phase 2 trial results for PIKTOR. The trial showed a 33% objective response rate and 7.4-month median progression-free survival, outperforming typical chemotherapy benchmarks. Despite a 45% stock decline, analysts highlight the drug's potential and manageable toxicity. Other firms also reiterated positive ratings, and the company appointed a new board member.